Immutep (IMMP) Income from Non-Controlling Interests (2011 - 2017)
Immutep's (IMMP) quarterly Income from Non-Controlling Interests came in at -$589775.1 in Q1 2017, down 256.81% YoY from $376106.8 in Q1 2016, and down 396.08% on a QoQ basis from $199195.6 in Q2 2016.
Immutep (IMMP) Income from Non-Controlling Interests (2011 - 2017) Analysis & Trends
Immutep (IMMP) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$589775.1 in Q1 2017.
- Quarterly Income from Non-Controlling Interests fell 256.81% year-over-year to -$589775.1 in Q1 2017, while the trailing twelve-month figure through Mar 2017 was -$555796.1 (changed N/A YoY) and the FY2016 annual result came in at $229235.4, up 618.15% from the prior year.
- Income from Non-Controlling Interests eased to -$589775.1 in Q1 2017, from $199195.6 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $199195.6 in Q2 2016 to a low of -$589775.1 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -589,775.11 |
| Jun 30, 2016 | 199,195.56 |
| Mar 31, 2016 | -165,290.84 |
| Jun 30, 2011 | 74.32 |